Comparative Pharmacology
Head-to-head clinical analysis: PORTIA 21 versus TRI LO SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORTIA 21 versus TRI LO SPRINTEC.
PORTIA-21 vs TRI LO SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
None Documented
None Documented
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Category C
Category C
Oral Contraceptive
Oral Contraceptive